A Randomized Multicenter Phase II Trial of Patupilone (EPO906) plus Prednisone versus Docetaxel (Taxotere) plus Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer

Next Previous
Trial Profile

A Randomized Multicenter Phase II Trial of Patupilone (EPO906) plus Prednisone versus Docetaxel (Taxotere) plus Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Patupilone (Primary) ; Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Apr 2012 Actual number of patients changed from 67 to 137 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top